Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-04-13

Clinical Trial Update: Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Pfizer-sponsored Phase 2 trial evaluating inotuzumab ozogamicin in acute lymphoblastic leukemia has completed and posted results in April 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Pfizer | Conditions: Acute Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-04-13